Lexaria Bioscience Corp. (LEXX)
NASDAQ: LEXX · Real-Time Price · USD
0.7423
-0.0081 (-1.08%)
At close: Mar 27, 2026, 4:00 PM EDT
0.7532
+0.0109 (1.47%)
After-hours: Mar 27, 2026, 6:16 PM EDT
Lexaria Bioscience Revenue
Lexaria Bioscience had revenue of $522.00K in the twelve months ending November 30, 2025, up 5.05% year-over-year. In the fiscal year ending August 31, 2025, Lexaria Bioscience had annual revenue of $705.92K with 52.05% growth.
Revenue (ttm)
$522.00K
Revenue Growth
+5.05%
P/S Ratio
35.39
Revenue / Employee
$74,571
Employees
7
Market Cap
18.47M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Aug 31, 2025 | 705.92K | 241.65K | 52.05% |
| Aug 31, 2024 | 464.28K | 238.07K | 105.24% |
| Aug 31, 2023 | 226.21K | -29.19K | -11.43% |
| Aug 31, 2022 | 255.40K | -467.34K | -64.66% |
| Aug 31, 2021 | 722.74K | 407.95K | 129.59% |
| Aug 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionLEXX News
- 3 days ago - Lexaria's Robust Patent Portfolio Continues to Grow - Accesswire
- 5 days ago - Lexaria's Oral GLP-1 Drug Strategy Validated by Industry - TheNewswire
- 25 days ago - Lexaria Announces New R&D Plans for 2026 - Accesswire
- 7 weeks ago - Lexaria Announces Positive Final Results From Human Pilot Study #5 - Accesswire
- 2 months ago - Lexaria Awarded Six Additional Patents - Accesswire
- 2 months ago - Lexaria Releases Annual Letter from the CEO - Accesswire
- 3 months ago - Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4 - Accesswire
- 3 months ago - Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus - Benzinga